The paullones: A family of pharmacological inhibitors of cyclin-dependent kinases and glycogen synthase kinase 3

Handbook of Experimental Pharmacology

Volumn 167, Issue , 2005, Pages 47-64

  Meijer, L ^a   Leost, M ^a   Lozach, O ^a   Schmitt, S ^a   Kunick, C ^b  

^a Protein Phosphorylation and Human Disease Group   (France)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Cancer; Cyclin dependent kinase; Glycogen synthase kinase; Malaria; Neurodegenerative disorders; Paullone

Indexed keywords

EID: 33845283967     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-26670-4_3     Document Type: Article

References (73)

1. Adams JA (2001) Kinetic and catalytic mechanisms of protein kinases. Chem Rev 101:2271-2290
2. Adams JL, Lee D (1999) Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases. Curr Opin Drug Discov Devel 2:96-109
3. Bain J, McLauchlan H, Elliott M, et al (2003) The specificities of protein kinase inhibitors: An update. Biochem J 371:199-204
4. Bertrand JA, Thieffine S, Vulpetti A, et al (2003) Structural characterization of the GSK-3b active site using selective and non-selective ATP-mimetic inhibitors. J Mol Biol 333:393-407
5. Bhat R, Xue Y, Berg S, et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278:45937-45945
6. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC, Greengard P (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402:669-671
7. Borgne A, Meijer L (1996) Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem 271:27847-27854
8. Bridges AJ (2001) Chemical inhibitors of protein kinases. Chem Rev 101:2541-2571
9. Capdeville R, Silberman S, Dimitrijevic S (2002a) Imatinib: The first 3 years. Eur J Cancer 38(Suppl 5):77-82
10. Capdeville R, Buchdunger E, Zimmermann J, et al (2002b) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493-502
11. Caricasole A (2003) The Wnt pathway, cell-cycle activation and beta-Amyloid: Novel therapeutic strategies in Alzheimer s disease? Trends Pharmacol Sci 24:233-238
12. Cohen P (2001) The role of protein phosphorylation in human health and disease. The Sir Hans Krebs Medal Lecture. Eur J Biochem 268:5001-5010
13. Cohen P (2002) Protein kinases-The major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309-315
14. Cohen P, Frame S (2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2:769-776
15. Cruz JC, Tseng HC, Goldman JA, et al (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471-483
16. De Strooper B, Woodgett J (2003) Alzheimer s disease: Mental plaque removal. Nature 423:392-393
17. Dhavan R, Tsai L-H (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2:749-759
18. Doble BW, Woodgett Jr. (2003) GSK-3: Tricks of the trade for a multi-Tasking kinase. J Cell Sci 116:1175-1186
19. Doerig C, Meijer L, Mottram J (2002) Protein kinases as drug targets in parasitic protozoa. Trends Parasitol 18:366-371
20. Dorronsoro I, Castro A, Martinez A (2002) Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs? Expert Opin Ther Patents 12:1527-1536
21. Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson C, Sallicandro P, Alano P, Jafarshad A, Baratte B, Kunick C, Parzy D, Pearl L, Doerig C, Meijer L (2004) Plasmodium falciparum glycogen synthase kinase-3: Molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta 1697:181-96
22. Dumas J (2001) Protein kinase inhibitors: Emerging pharmacophores 1997-2000. Expert Opin Ther Patents 11:405-429
23. Eldar-Finkelman H (2002) Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 8:126-132
24. Fischer PM (2003) CDK versus GSK-3 inhibition: A purple haze no longer? Chem Biol 10:1144-1146
25. Fischer PM, Endicott J, Meijer L (2003) Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res 5:235-248
26. Garcia-Echeverria C, Traxler P, Evans DB (2000) ATP site-directed competitive and irreversible inhibitors of protein kinases. Med Res Rev 20:28-57
27. Gerber PR (1998) Charge distribution from a simple molecular orbital type calculation and non-bonding interaction terms in the force field MAB. J Comput Aided Mol Des 12:37-51
28. Godl K, Wissing J, Kurtenbach A, et al (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci USA 100:15434-15439
29. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391-426
30. Gussio R, Zaharevitz D, McGrath CF, et al (2000) Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anticancer Drug Des 15: 53-66
31. Hanks SK (2003) Genomic analysis of the eukaryotic protein kinase superfamily: A perspective. Genome Biol 4:111:1-7
32. Hardcastle IR, Golding BT, Griffin RJ (2002) Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol 42:325-348
33. Harper JW, Adams PD (2001) Cyclin-dependent kinases. Chem Rev 101:2511-2526
34. Jackson MD, Denu JM (2001) Molecular reactions of protein phosphatases-insights from structure and chemistry. Chem Rev 101:2313-2340
35. Kaytor MD, Orr HT (2002) The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 12:275-278
36. Kennelly PJ (2001) Protein phosphatases-A phylogenetic perspective. Chem Rev 101:2291-2312
37. Knockaert M, Meijer L (2002) Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem Pharmacol 64:819-825
38. Knockaert M, Greengard P, Meijer L (2002a) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 23:417-425
39. Knockaert M, Viking K, Schmitt S (2002b) Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J Biol Chem 277:25493-25501
40. Krupa A, Srinivasan N (2002) The repertoire of protein kinases encoded in the draft version of the human genome: Atypical variations and uncommon domain combinations. Genome Biol 3:Research0066.1-006614
41. Kunick C (1992) Synthese von 7,12-Dihydro-indolo[3,2-d][1]benzazepin-6-(5 H)-onen und 6,11-Dihydro-Thieno-[3-,2-:2,3]azepino[4,5-b]indol-5(4 H)-on. Arch Pharm (Weinheim) 325:297-299
42. Kunick C, Schultz C, Lemcke T (2000) 2-Substituted paullones: DDK1/cyclin B-inhibiting property and in vitro antiproliferative activity. Bioorg Med Chem Lett 10:567-569
43. Kunick C, Lauenroth K, Wieking K, et al (2004) Evaluation and comparison of 3D-QSARmodels for CDK1, CDK5 and GSK-3 inhibition by paullones. J Med Chem 47:22-36
44. Lahusen T, De Siervi A, Kunick C (2003) Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential. Mol Carcinog 36:183-194
45. Leclerc S, Garnier M, Hoessel R (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer-s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276:251-260
46. Leost M, Schultz C, Link A (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 267:5983-5994
47. Lyon MA, Ducruet AP, Wipf P, et al (2002) Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov 1:961-976
48. Maccioni RB, Otth C, Concha II, et al (2001) The protein kinase Cdk5. Structural aspects, roles in neurogenesis and involvement in Alzheimer-s pathology. Eur J Biochem 268:1518-1527
49. Malumbres M, Barbacid M (2001) To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 1:222-231
50. Malumbres M, Ortega S, Barbacid M (2000) Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol Chem 381:827-838
51. Manning G, Whyte DB, Martinez R, et al (2002) The protein kinase complement of the human genome. Science 298:1912-1934
52. Martinez A, Castro A, Dorronsoro I, et al (2002) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22:373-384
53. Meijer L, Borgne A, Mulner O, et al (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536
54. Meijer L, Skaltsounis AL, Magiatis P, et al (2003) GSK-3 selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10: 1-12
55. Monaco EA 3rd, Vallano ML (2003) Cyclin-dependent kinase inhibitors: Dancer killers to neuronal guardians. Curr Med Chem 10:367-379
56. Monks A, Scudiero DA, Johnson GS, et al (1997) The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets. Anti-Cancer Drug Des 12:533-541
57. Morgan D (1997) Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291
58. Noble W, Olm V, Takata K, et al (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:555-565
59. Oda Y, Owa T, Sato T, et al (2003) Quantitative chemical proteomics for identifying candidate drug targets. Anal Chem 75:2159-2165
60. Paull KD (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-Assisted evaluation of differential cytotoxicity data. Cancer Res 52:3892-3900
61. Paull KD (1995) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: Foye WO (ed) Cancer Chemotherapeutic Agents. American Chemical Society Books, Washington, pp 8-45
62. Pavletich NP (1999) Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 287:821-828
63. Phiel CJ, Wilson CA, Lee VM, et al (2003) GSK-3alpha regulates production of Alzheimer-s disease amyloid-beta peptides. Nature 423:435-439
64. Primot A, Baratte B, Gompel M, et al (2000) Purification of GSK-3 by affinity chromatography on immobilized axin. Protein Expr Purif 20:394-404
65. Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8:S32-S37
66. Schultz C, Link A, Leost M, et al (1999) Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem 42:2909-2919
67. Sim AT, Ludowyke RI (2002) The complex nature of protein phosphatases. IUBMB Life 53:283-286
68. Smith PD, Crocker SJ, Jackson-Lewis V, et al (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson-s disease. Proc Natl Acad Sci USA 100:13650-13655
69. Sridhar R, Hanson-Painton O, Cooper DR (2000) Protein kinases as therapeutic targets. Pharm Res 17:1345-1353
70. Vesely J, Havlicek L, Strnad M, et al (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224:771-786
71. Wang J, Liu SH, Fu YP, et al (2003) Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat Neurosci 6:1039-1047
72. Wieking K, Knockaert M, Leost M, et al (2002) Synthesis of paullones with aminoalkyl side chains. Arch Pharm (Weinheim) 335:311-317
73. Zaharevitz D, Gussio R, Leost M, et al (1999) Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res 59:2566-2569